Protein-based XBB COVID Vaccine Coming Soon

Novavax, Inc. today announced its operational highlights for the second quarter ended June 30, 2023. 

"During the first half of 2023, Novavax has been focused on execution, making significant progress on all three of our key priorities. We have initiated the filing for authorization of our updated XBB COVID vaccine in the U.S., with submissions in the European Union and Canada to follow. We are manufacturing at commercial scale in support of our plan to deliver our vaccine on time for the fall season," said John C. Jacobs, President and Chief Executive Officer, Novavax, in a press release on August 8, 2023.

"We continue to work towards deriving additional value from our pipeline and technology and will be advancing our COVID-Influenza Combination vaccine candidate through the next stage gates and towards late-stage development."

Novavax also received first Full Marketing Authorization in Europe for Nuvaxovid™ as a primary series in individuals aged 12 and older and as a booster in adults aged 18 and older.

Since authorization, Nuvaxovid™, a protein-based vaccine, has been distributed in about 40 markets.

On July 11, 2022, Novavax announced an agreement with the U.S. HHS to secure 3.2 million doses of Novavax's COVID-19 vaccine.

And the company initiated the rolling submission of a U.S. Biologics License Application for full approval of the Novavax COVID-19 Vaccine, Adjuvanted for adults and adolescents aged 12 through 18.